{"id":59582,"date":"2026-03-16T14:17:58","date_gmt":"2026-03-16T06:17:58","guid":{"rendered":"https:\/\/flcube.com\/?p=59582"},"modified":"2026-03-16T14:17:59","modified_gmt":"2026-03-16T06:17:59","slug":"jjs-erda-idrs-shows-89-complete-response-in-nmibc-intravesical-erdafitinib-system-advances-to-phase-ii-iii","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59582","title":{"rendered":"J&amp;J&#8217;s Erda-iDRS Shows 89% Complete Response in NMIBC \u2013 Intravesical Erdafitinib System Advances to Phase II\/III"},"content":{"rendered":"\n<p><strong>Johnson &amp; Johnson<\/strong> (J&amp;J, <a href=\"https:\/\/www.google.com\/finance\/quote\/JNJ:NYSE\">NYSE: JNJ<\/a>) announced <strong>positive Phase I results<\/strong> for <strong>Erda-iDRS<\/strong>, an <strong>investigational intravesical drug-releasing system<\/strong> delivering <strong>erdafitinib<\/strong> directly to the bladder for <strong>non-muscle-invasive bladder cancer (NMIBC)<\/strong> with <strong>FGFR alterations<\/strong>. The <strong>open-label, multicenter study<\/strong> demonstrated <strong>89% complete response (CR) in intermediate-risk patients<\/strong> with <strong>18-month median duration of response<\/strong>, and <strong>20-month median recurrence-free survival in high-risk patients<\/strong> with <strong>83% 12-month RFS<\/strong>. The <strong>localized three-month sustained release<\/strong> approach aims to <strong>minimize systemic exposure<\/strong> while maintaining efficacy, supporting <strong>ongoing Phase II\/III development<\/strong> across risk settings.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-phase-i-clinical-results\">Phase I Clinical Results<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Cohort<\/th><th>Primary Endpoint<\/th><th>Key Efficacy Results<\/th><th>Durability<\/th><\/tr><\/thead><tbody><tr><td><strong>Intermediate-Risk NMIBC<\/strong><\/td><td>Safety (met)<\/td><td><strong>89% complete response rate<\/strong><\/td><td>Median duration of CR: <strong>18 months<\/strong><\/td><\/tr><tr><td><strong>High-Risk NMIBC<\/strong><\/td><td>Safety (met)<\/td><td>Median recurrence-free survival: <strong>20 months<\/strong><\/td><td>12-month RFS rate: <strong>83%<\/strong><\/td><\/tr><tr><td><strong>Overall<\/strong><\/td><td>Safety + encouraging efficacy<\/td><td>Prolonged responses over time<\/td><td>Supports Phase II\/III advancement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Study Design:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Population:<\/strong> Intermediate-risk and high-risk NMIBC with select FGFR alterations<\/li>\n\n\n\n<li><strong>Treatment:<\/strong> Intravesical erdafitinib-releasing system (Erda-iDRS)<\/li>\n\n\n\n<li><strong>Duration:<\/strong> Three-month sustained local release<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-mechanism\">Product Profile &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Erda-iDRS Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Component<\/strong><\/td><td>Erdafitinib (oral FGFR kinase inhibitor \u2013 approved for metastatic urothelial carcinoma)<\/td><\/tr><tr><td><strong>Delivery System<\/strong><\/td><td>Intravesical drug-releasing system (iDRS)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Prolonged local erdafitinib release directly into bladder<\/td><\/tr><tr><td><strong>Duration of Release<\/strong><\/td><td>Three months<\/td><\/tr><tr><td><strong>Key Advantage<\/strong><\/td><td>Localized treatment; minimizes systemic exposure; reduces systemic adverse events<\/td><\/tr><tr><td><strong>Target Population<\/strong><\/td><td>NMIBC with FGFR alterations (intermediate-risk and high-risk)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Scientific Rationale:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>FGFR Alterations:<\/strong> Present in ~20% of bladder cancers; drive tumor growth and progression<\/li>\n\n\n\n<li><strong>Intravesical Advantage:<\/strong> Direct bladder delivery vs. oral systemic administration; reduced toxicity (hyperphosphatemia, dermatologic AEs)<\/li>\n\n\n\n<li><strong>Sustained Release:<\/strong> Three-month duration reduces treatment frequency vs. standard intravesical BCG or chemotherapy<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-amp-market-opportunity\">Strategic Context &amp; Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>NMIBC Market<\/strong><\/td><td>70% of bladder cancers diagnosed as NMIBC; high recurrence rates (50-70% within 5 years)<\/td><\/tr><tr><td><strong>Unmet Need<\/strong><\/td><td>BCG failure\/unavailability drives demand for novel intravesical therapies; FGFR-targeted approach novel<\/td><\/tr><tr><td><strong>Erdafitinib Expansion<\/strong><\/td><td>Leverages approved metastatic indication (Balversa) for earlier-stage disease; lifecycle management<\/td><\/tr><tr><td><strong>J&amp;J Urology Franchise<\/strong><\/td><td>Complements robotic surgery and diagnostics; integrated bladder cancer care pathway<\/td><\/tr><tr><td><strong>Competitive Timing<\/strong><\/td><td>First FGFR-targeted intravesical therapy; potential for BCG replacement in FGFR+ patients<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Product<\/th><th>Mechanism<\/th><th>NMIBC Status<\/th><th>Erda-iDRS Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Ferring\/BCG<\/strong><\/td><td>BCG (bacillus Calmette-Gu\u00e9rin)<\/td><td>Immunotherapy<\/td><td>Standard of care (high-risk)<\/td><td>FGFR-targeted vs. immunotherapy; for BCG failures<\/td><\/tr><tr><td><strong>Merck<\/strong><\/td><td>Keytruda (pembrolizumab)<\/td><td>PD-1 inhibitor<\/td><td>Approved (BCG-unresponsive high-risk)<\/td><td>Intravesical local delivery vs. systemic immunotherapy<\/td><\/tr><tr><td><strong>Janssen (J&amp;J)<\/strong><\/td><td><strong>Erda-iDRS<\/strong><\/td><td><strong>Intravesical FGFR inhibitor<\/strong><\/td><td><strong>Phase I (completed); Phase II\/III ongoing<\/strong><\/td><td><strong>First targeted intravesical therapy; 89% CR; 18-month durability<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-outlook\">Development Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Timeline<\/th><th>Objectives<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase I<\/strong><\/td><td>Completed<\/td><td>Safety, feasibility, preliminary efficacy in intermediate\/high-risk NMIBC<\/td><\/tr><tr><td><strong>Phase II<\/strong><\/td><td>Ongoing<\/td><td>Expansion cohorts; FGFR biomarker refinement; durability confirmation<\/td><\/tr><tr><td><strong>Phase III<\/strong><\/td><td>2026-2028<\/td><td>Registrational study vs. standard of care (BCG or chemotherapy)<\/td><\/tr><tr><td><strong>Regulatory Strategy<\/strong><\/td><td>2028-2029<\/td><td>NDA filing for FGFR+ NMIBC; potential breakthrough therapy designation<\/td><\/tr><tr><td><strong>Companion Diagnostic<\/strong><\/td><td>2026-2027<\/td><td>FGFR alteration detection (FISH or NGS) for patient selection<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Phase II\/III development, FGFR biomarker validation, and competitive positioning for Erda-iDRS in non-muscle-invasive bladder cancer. Actual results may differ due to intravesical delivery technical challenges, FGFR testing adoption, and competitive dynamics with BCG and immunotherapy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) announced positive Phase I results for Erda-iDRS, an investigational&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11,22],"tags":[16,17,150,149,858],"class_list":["post-59582","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","category-medical-device","tag-cancer","tag-clinical-trial-results","tag-jj","tag-johnson-johnson","tag-nyse-jnj"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>J&amp;J&#039;s Erda-iDRS Shows 89% Complete Response in NMIBC \u2013 Intravesical Erdafitinib System Advances to Phase II\/III - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) announced positive Phase I results for Erda-iDRS, an investigational intravesical drug-releasing system delivering erdafitinib directly to the bladder for non-muscle-invasive bladder cancer (NMIBC) with FGFR alterations. The open-label, multicenter study demonstrated 89% complete response (CR) in intermediate-risk patients with 18-month median duration of response, and 20-month median recurrence-free survival in high-risk patients with 83% 12-month RFS. The localized three-month sustained release approach aims to minimize systemic exposure while maintaining efficacy, supporting ongoing Phase II\/III development across risk settings.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59582\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"J&amp;J&#039;s Erda-iDRS Shows 89% Complete Response in NMIBC \u2013 Intravesical Erdafitinib System Advances to Phase II\/III\" \/>\n<meta property=\"og:description\" content=\"Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) announced positive Phase I results for Erda-iDRS, an investigational intravesical drug-releasing system delivering erdafitinib directly to the bladder for non-muscle-invasive bladder cancer (NMIBC) with FGFR alterations. The open-label, multicenter study demonstrated 89% complete response (CR) in intermediate-risk patients with 18-month median duration of response, and 20-month median recurrence-free survival in high-risk patients with 83% 12-month RFS. The localized three-month sustained release approach aims to minimize systemic exposure while maintaining efficacy, supporting ongoing Phase II\/III development across risk settings.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59582\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-16T06:17:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-16T06:17:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59582#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59582\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"J&amp;J&#8217;s Erda-iDRS Shows 89% Complete Response in NMIBC \u2013 Intravesical Erdafitinib System Advances to Phase II\\\/III\",\"datePublished\":\"2026-03-16T06:17:58+00:00\",\"dateModified\":\"2026-03-16T06:17:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59582\"},\"wordCount\":519,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Clinical trial results\",\"J&amp;J\",\"Johnson &amp; Johnson\",\"NYSE: JNJ\"],\"articleSection\":[\"Company\",\"Drug\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59582#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59582\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59582\",\"name\":\"J&amp;J's Erda-iDRS Shows 89% Complete Response in NMIBC \u2013 Intravesical Erdafitinib System Advances to Phase II\\\/III - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-16T06:17:58+00:00\",\"dateModified\":\"2026-03-16T06:17:59+00:00\",\"description\":\"Johnson & Johnson (J&J, NYSE: JNJ) announced positive Phase I results for Erda-iDRS, an investigational intravesical drug-releasing system delivering erdafitinib directly to the bladder for non-muscle-invasive bladder cancer (NMIBC) with FGFR alterations. The open-label, multicenter study demonstrated 89% complete response (CR) in intermediate-risk patients with 18-month median duration of response, and 20-month median recurrence-free survival in high-risk patients with 83% 12-month RFS. The localized three-month sustained release approach aims to minimize systemic exposure while maintaining efficacy, supporting ongoing Phase II\\\/III development across risk settings.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59582#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59582\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59582#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"J&amp;J&#8217;s Erda-iDRS Shows 89% Complete Response in NMIBC \u2013 Intravesical Erdafitinib System Advances to Phase II\\\/III\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"J&amp;J's Erda-iDRS Shows 89% Complete Response in NMIBC \u2013 Intravesical Erdafitinib System Advances to Phase II\/III - Insight, China&#039;s Pharmaceutical Industry","description":"Johnson & Johnson (J&J, NYSE: JNJ) announced positive Phase I results for Erda-iDRS, an investigational intravesical drug-releasing system delivering erdafitinib directly to the bladder for non-muscle-invasive bladder cancer (NMIBC) with FGFR alterations. The open-label, multicenter study demonstrated 89% complete response (CR) in intermediate-risk patients with 18-month median duration of response, and 20-month median recurrence-free survival in high-risk patients with 83% 12-month RFS. The localized three-month sustained release approach aims to minimize systemic exposure while maintaining efficacy, supporting ongoing Phase II\/III development across risk settings.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59582","og_locale":"en_US","og_type":"article","og_title":"J&amp;J's Erda-iDRS Shows 89% Complete Response in NMIBC \u2013 Intravesical Erdafitinib System Advances to Phase II\/III","og_description":"Johnson & Johnson (J&J, NYSE: JNJ) announced positive Phase I results for Erda-iDRS, an investigational intravesical drug-releasing system delivering erdafitinib directly to the bladder for non-muscle-invasive bladder cancer (NMIBC) with FGFR alterations. The open-label, multicenter study demonstrated 89% complete response (CR) in intermediate-risk patients with 18-month median duration of response, and 20-month median recurrence-free survival in high-risk patients with 83% 12-month RFS. The localized three-month sustained release approach aims to minimize systemic exposure while maintaining efficacy, supporting ongoing Phase II\/III development across risk settings.","og_url":"https:\/\/flcube.com\/?p=59582","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-16T06:17:58+00:00","article_modified_time":"2026-03-16T06:17:59+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59582#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59582"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"J&amp;J&#8217;s Erda-iDRS Shows 89% Complete Response in NMIBC \u2013 Intravesical Erdafitinib System Advances to Phase II\/III","datePublished":"2026-03-16T06:17:58+00:00","dateModified":"2026-03-16T06:17:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59582"},"wordCount":519,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Clinical trial results","J&amp;J","Johnson &amp; Johnson","NYSE: JNJ"],"articleSection":["Company","Drug","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59582#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59582","url":"https:\/\/flcube.com\/?p=59582","name":"J&amp;J's Erda-iDRS Shows 89% Complete Response in NMIBC \u2013 Intravesical Erdafitinib System Advances to Phase II\/III - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-16T06:17:58+00:00","dateModified":"2026-03-16T06:17:59+00:00","description":"Johnson & Johnson (J&J, NYSE: JNJ) announced positive Phase I results for Erda-iDRS, an investigational intravesical drug-releasing system delivering erdafitinib directly to the bladder for non-muscle-invasive bladder cancer (NMIBC) with FGFR alterations. The open-label, multicenter study demonstrated 89% complete response (CR) in intermediate-risk patients with 18-month median duration of response, and 20-month median recurrence-free survival in high-risk patients with 83% 12-month RFS. The localized three-month sustained release approach aims to minimize systemic exposure while maintaining efficacy, supporting ongoing Phase II\/III development across risk settings.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59582#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59582"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59582#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"J&amp;J&#8217;s Erda-iDRS Shows 89% Complete Response in NMIBC \u2013 Intravesical Erdafitinib System Advances to Phase II\/III"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59582","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59582"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59582\/revisions"}],"predecessor-version":[{"id":59584,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59582\/revisions\/59584"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59582"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59582"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59582"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}